Adaptive Biotechnologies Corporation (ADPT) stock declined over -1.58% intraday to trade at $8.09 a share on NASDAQ. The stock opened with a loss of -0.37% at $7.99 and touched an intraday high of $8.19, falling -1.58% against the last close of $8.22. The stock went to a low of $7.77 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue154.34 Million
5Y Sales Change-
Fiscal Year Ends2021-12-30
IndustryLife Sciences Tools and Services
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ, a clinical diagnostic product for the detection and monitoring of minimal residual disease in patients with multiple myeloma, B cell acute lymphoblastic leukemia, and chronic lymphocytic leukemia, as well as available as a CLIA-validated laboratory developed test for patients with other lymphoid cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Adaptive Biotechnologies Corporation (NASDAQ: ADPT) stock price is $8.09 as of the last check on Thursday, June 30. During the trading session, ADPT stock reached the peak price of $8.19 while $7.77 was the lowest point it dropped to.
The NASDAQ listed ADPT is part of Life Sciences Tools and Services industry that operates in the broader Health Care sector. Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ, a platform and core immunosequencing product that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection.
Mr. Francis T. Lo
Chief People Officer
Mr. Chad M. Robins M.B.A, M.B.A.
Co-Founder, CEO & Chairman
Ms. Julie Rubinstein
Dr. Harlan S. Robins Ph.D.
Co-Founder & Chief Scientific Officer
ADPT stock traded closed the last session at $8.09, which is $-0.13 or -1.58% lower than its previous close of $8.22. ADPT's current trading price is 35.85% lower than its 52-week high of $42.13 where as its distance from 52-week low of 5.95% is -80.80%.
Number of ADPT employees currently stands at -. ADPT operates from 1165 Eastlake Avenue East, Suite 200, Seattle, WA 98102, United States.
Official Webiste of $ADPT is: https://www.adaptivebiotech.com
ADPT stock volume for the day was 1,221,540 shares while in the previous session number of ADPT shares traded was 1,208,471 . The average number of ADPT shares traded daily for last 3 months was 1.81 Million.
The percentage change in ADPT stock occurred in the recent session was -1.58% while the dollar amount for the price change in ADPT stock was $-0.13.
In the recent session, the day high for ADPT stock was $8.19 while the low for ADPT stock touched on the day was $7.77.
The market value of ADPT currently stands at 1.14 Billion with its latest stock price at $8.09 and 141.7 Million of its shares outstanding.